Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Milestone Pharmaceuticals Inc. Common Shares

Thank you for your interest in Milestone Pharmaceuticals. While we encourage you to explore opportunities with our company, we urge you to be cautious and wary of recruitment scams in which fraudsters pose as representatives of Milestone Pharma. All current openings are available to view on our Careers page. https://milestonepharmaceuticals.applytojob.com/

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker designed by Milestone and being developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of PSVT as they occur. Milestone is actively recruiting patients for a Phase 3 clinical trial of etripamil for the treatment of PSVT. Milestone plans to initiate a Phase 2 clinical trial in atrial fibrillation, another rapid heart rate condition, and expects to subsequently initiate an additional Phase 2 clinical trial in angina to establish proof-of-concept for the broader use of etripamil.

RTW Investments

Amplitude Venture Capital

Tekla Capital Management

BDC Capital Corporation

Boxer Capital

Novo Holdings

GO CAPITAL

Pappas Capital

Domain Associates

Fonds de solidarité FTQ

Forbion Capital Partners

Milestone Pharmaceuticals, Inc.

Today, there is a critical need for an innovative, novel treatment solution to support patients experiencing debilitating heart conditions.
 
Recently, we had the opportunity to join the #cardiovascular community in Washington D.C. to discuss the latest clinical trials to advance treatments for these conditions at the Global CVCT - Cardiovascular Clinical Trialists Forum. From our clinical development program, we shared the latest results on our lead investigational product, etripamil, for PSVT and AFib-RVR.
 
The results from our Phase 3 RAPID study for PSVT and our Phase 2 ReVeRA study for AFib-RVR demonstrate our commitment to help alleviate the provider burden in diagnosing and treating these debilitating and life-altering cardiovascular conditions and help patients actively self-manage their condition outside the healthcare setting.
 
You can learn more about our clinical development program here: https://bit.ly/47Dzq6m
 
#CVCT2023 #ClinicalTrials #ClinicalResearch

#DYK that the prevalence of atrial fibrillation (AFib) is expected to grow to approximately 10 million by 2025 and up to about 12 million by 2030, according to the American Heart Association? 
 
Recently at the American Heart Association Scientific Sessions 2023, we presented positive results from our ReVeRA Phase 2 clinical trial evaluating etripamil in AFib with rapid ventricular rate (AFib-RVR), a serious condition which presents in a subset of AFib patients, and is characterized by more severe episodic symptoms including heart palpitations, shortness of breath, dizziness, and/or weakness. 
 
One of the study investigators, Dr. James Ip from Weill Cornell Medicine, sat down with HCPLive to discuss the unmet needs for patients with AFib-RVR and the potential of etripamil nasal spray. 
 
Read more about the results from the study here: https://lnkd.in/ewrfDT8e
 
You can tune into Dr. Ip’s interview below. 
 
#AHA23 #AFib

Attending the Global CVCT - Cardiovascular Clinical Trialists Forum in Washington D.C. this weekend?
 
We look forward to sharing data on the efficacy and safety of etripamil, an investigational new drug, from our clinical trials to treat patients with paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular response (AFib-RVR). 
 
Let us know if you plan to attend in the comments. Members of our leadership team, including David Bharucha, MD, PhD and Anita Holz, MSN, CRNP, will be in attendance. We look forward to seeing you there! 
 
#CVCT2023 #ClinicalTrials #ClinicalResearch

Today, we reported our financial results for the Third Quarter 2023. Learn more about these results and progress in our clinical development program here: https://lnkd.in/e7hrGyfc

Tomorrow is the last day of #AHA23! Stop by our booth (#2911/B2659) today and tomorrow to learn more about the newly presented results from our ReVeRA Phase 2 clinical study of etripamil in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). We look forward to discussing how we are addressing the unmet need for patients living with AFib-RVR and paroxysmal supraventricular tachycardia (PSVT).  
  
You can learn more about the results of the study, simultaneously published in Circulation: Arrhythmia and Electrophysiology here: https://lnkd.in/ewrfDT8e
 
#Milestone #AFib #SVTAwareness

As part of a Featured Scientific Session at the @American Heart Association, today, we presented positive results from our ReVeRA Phase 2 clinical study of etripamil in AFib-RVR. The results were also simultaneously published in Circulation: Arrhythmia and Electrophysiology.
 
Patients with AFib-RVR continue to face a significant unmet need and our market research data suggests 30-40 percent of patients with AFib experience one or more symptomatic episodes of AFib-RVR requiring treatment. 
 
At Milestone, we are committed to helping improve the lives of people living with cardiovascular conditions. We plan to share an update on the continued development of self-administered etripamil nasal spray for AFib-RVR in the coming weeks.
 
You can learn more about the results here:

https://lnkd.in/ewrfDT8e
 
#Milestone #AFib #AHA23

Attending American Heart Association Scientific Sessions in Philadelphia from November 11-13?
 
Our team will be on the ground and looks forward to connecting and learning more about the latest advancements in #hearthealth. Come stop by our booth #2911/B2659 to learn more about the latest updates in #PSVT and #AFib and how we are working to address current unmet needs for patients. 
 
We look forward to seeing you there! 
 
#AHA23 #SVTAwareness

Join the Milestone Pharmaceuticals team the morning of Saturday, November 11 for a MedscapeLIVE Event where we will dive into paroxysmal supraventricular tachycardia (PSVT). 
 
PSVT is a life-altering disease affecting 1 in 300 patients and is characterized by spontaneous episodes of ventricular contractions exceeding rates of 100 beats per minute. During this symposium, experts will discuss hot topics on PSVT including clinical burden of disease, guideline recommendations, and current as well as emerging treatment strategies for PSVT. #AHA #HeartHealth #PSVT #SVTAwareness

We look forward to having you join us, and you can register here:

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	819K -	2.60M 217.83%	4.38M 68.11%	4.64M 6.06%	4.38M 5.54%	2.26M 48.38%	3.98M 75.92%
accumulated other comprehensive income loss	-1.63M -	-1.63M 0%	-1.63M 0%	-1.63M 0%	-1.63M 0%		48.46M -
cash and cash equivalents	10.88M -	85.95M 689.95%	119.82M 39.41%	72.31M 39.65%	114.14M 57.85%	7.64M 93.31%	13.76M 80.20%
cash and short term investments	26.91M -	85.98M 219.47%	119.82M 39.36%	142.31M 18.77%	114.14M 19.79%	64.58M 43.42%	66.00M 2.20%
common stock	1.23M -	2.04M 66.04%	226.25M 10,995.88%	251.68M 11.24%	251.90M 0.09%	273.90M 8.73%	260.50M 4.89%
deferred revenue
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory			-578K -	-725K 25.43%	-356K 50.90%	-331K 7.02%
long term debt			184K -	696K 278.26%	474K 31.90%	2.00M 321.10%	49.77M 2,393.59%
long term investments
net debt	-10.88M -	-85.95M 689.95%	-119.30M 38.81%	-71.37M 40.18%	-113.44M 58.95%	-5.14M 95.46%	38.02M 838.87%
net receivables	543K -	677K 24.68%	836K 23.49%	948K 13.40%	483K 49.05%	1.21M 151.14%	3.85M 217.48%
other assets
other current assets	100K -	1.40M 1,298%	2.42M 73.32%	6.15M 153.94%	4.66M 24.35%	6.34M 36.11%	3.18M 49.84%
other current liabilities	786K -	1.93M 145.55%	3.62M 87.62%	1.27M 64.84%	2.17M 70.23%	3.38M 56.02%	2.70M 20.17%
other liabilities
other non current assets
other non current liabilities	59.10M -	138.76M 134.77%					1.46M -
othertotal stockholders equity	739K -	1.03M 39.65%	3.81M 268.70%	56.54M 1,385.86%	68.65M 21.43%	58.79M 14.37%	33.83M 42.45%
preferred stock	1.63M -	1.62M 0.61%
property plant equipment net	35K -	30K 14.29%	929K 2,996.67%	1.29M 38.64%	926K 28.11%	2.68M 189.42%	2.19M 18.13%
retained earnings	-35.09M -	-58.27M 66.08%	-113.50M 94.78%	-163.47M 44.02%	-206.32M 26.22%	-266.34M 29.09%	-326.03M 22.41%
short term debt			330K -	245K 25.76%	224K 8.57%	495K 120.98%	546K 10.30%
short term investments	16.03M -	29K 99.82%		70M -		56.95M -	52.24M 8.26%
tax assets
tax payables	4K -	56K 1,300%
total assets	27.59M -	88.08M 219.25%	123.43M 40.13%	149.97M 21.51%	119.85M 20.09%	74.48M 37.85%	75.23M 1.00%
total current assets	27.55M -	88.05M 219.55%	122.50M 39.12%	148.69M 21.38%	118.92M 20.02%	71.80M 39.62%	73.03M 1.71%
total current liabilities	1.60M -	4.53M 182.43%	8.33M 83.70%	6.16M 26.04%	6.78M 10.00%	6.14M 9.39%	7.23M 17.71%
total debt			514K -	941K 83.07%	698K 25.82%	2.49M 256.88%	51.77M 1,978.48%
total investments	16.03M -	29K 99.82%		70M -		56.95M -	52.24M 8.26%
total liabilities	60.71M -	143.29M 136.03%	8.51M 94.06%	6.86M 19.46%	7.25M 5.75%	8.13M 12.22%	58.45M 618.56%
total liabilities and stockholders equity	27.59M -	88.08M 219.25%	123.43M 40.13%	149.97M 21.51%	119.85M 20.09%	74.48M 37.85%	75.23M 1.00%
total non current assets	35K -	30K 14.29%	929K 2,996.67%	1.29M 38.64%	926K 28.11%	2.68M 189.42%	2.19M 18.13%
total non current liabilities	59.10M -	138.76M 134.77%	184K 99.87%	696K 278.26%	474K 31.90%	2.00M 321.10%	51.23M 2,466.58%
total stockholders equity	-33.12M -	-55.21M 66.70%	114.92M 308.15%	143.12M 24.54%	112.60M 21.32%	66.35M 41.08%	16.77M 74.72%

COM:MILESTONEPHARMA

Milestone Pharmaceuticals, Inc.

Last Close

1.85

22/11 21:00

Market Cap

98.12M

Beta: -

Volume Today

276.50K

Avg: -

Preview